|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Treatment of inflammatory bowel disease:A review of medical therapy显示文摘Crohn’s disease (CD) and ulcerative colitis (UC) are chronic inflammatory diseases of the gastrointestinal tract. While a cure remains elusive, both can be treated with medications that induce and maintain remission. With the recent advent of therapies that inhibit tumor necrosis factor (TNF) alpha the overlap in medical therapies for UC and CD has become greater. Although 5-ASA agents have been a mainstay in the treatment of both CD and UC, the data for their efficacy in patients with CD, particularly as maintenance therapy, are equivocal. Antibiotics may have a limited role in the treatment of colonic CD. Steroids continue to be the first choice to treat active disease not responsive to other more conservative therapy; non- systemic steroids such as oral and rectal budesonide for ileal and right-sided CD and distal UC respectively are also effective in mild-moderate disease. 6-mercaptopurine (6-MP) and its prodrug azathioprine are steroid-sparing immunomodulators effective in the maintenance of remission of both CD and UC, while methotrexate may be used in both induction and maintenance of CD. Infliximab and adalimumab are anti-TNF agents approved in the US and Europe for the treatment of Crohn's disease, and infliximab is also approved for the treatment of UC. | Patricia L Kozuch Stephen B Hanauer | 2008 | World Journal of Gastroenterology2008，14，3： | 21 |
| 2 | 溃疡性结肠炎显示文摘溃疡性结肠炎(ulcerativecolitis,uc)是一种消化道炎症性疾病,病变主要位于结直肠。UC好发于青年人,发达国家的人群患病率较高。UC表现为结直肠弥漫性、连续性浅表炎症,以及相应的组织学改变。下消化道内镜或影像检查可以明确诊断。目前尚未发现UC的明确病因,其发病机制与遗传易感个体的结肠内环境变化有关,具有慢性、终身、易复发的病程特点。 | Alexander C Ford Paul Moayyedl Steven B Hanauer Joseph B Kirsner 谭蓓 吴东 | 2017 | 英国医学杂志中文版2017，20，7： | 7 |
| 3 | Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial显示文摘 | Stephen B Hanauer Brian G Feagan Gary R Lichtenstein Lloyd F Mayer S Schreiber Jean Frederic Colombel Daniel Rachmilewitz Douglas C Wolf Allan Olson Weihang Bao Paul Rutgeerts | 2002 | The Lancet2002，，9317： | 6 |
| 4 | Human Anti–Tumor Necrosis Factor Monoclonal Antibody (Adalimumab) in Crohn’s Disease: the CLASSIC-I Trial显示文摘 | Stephen B. Hanauer William J. Sandborn Paul Rutgeerts Richard N. Fedorak Milan Lukas Donald MacIntosh Remo Panaccione Douglas Wolf Paul Pollack | 2006 | Gastroenterology2006，，2： | 4 |
| 5 | <ce:link locator='fx1'/> Adalimumab for Maintenance of Clinical Response and Remission in Patients With Crohn’s Disease: The CHARM Trial显示文摘 | Jean–Frédéric Colombel William J. Sandborn Paul Rutgeerts Robert Enns Stephen B. Hanauer Remo Panaccione Stefan Schreiber Dan Byczkowski Ju Li Jeffrey D. Kent Paul F. Pollack | 2007 | Gastroenterology2007，，1： | 4 |
| 6 | Early Mucosal Healing With Infliximab Is Associated With Improved Long-term Clinical Outcomes in Ulcerative Colitis显示文摘 | Jean Frédéric Colombel Paul Rutgeerts Walter Reinisch Dirk Esser Yanxin Wang Yinghua Lang Colleen W. Marano Richard Strauss Bj?rn J. Oddens Brian G. Feagan Stephen B. Hanauer Gary R. Lichtenstein Daniel Present Bruce E. Sands William J. Sandborn | 2011 | Gastroenterology2011，，4： | 3 |
| 7 | Management of Crohn’s disease in adults显示文摘 | Stephen B Hanauer William Sandborn | 2001 | The American Journal of Gastroenterology2001，，3： | 2 |
| 8 | <ce:link locator='fx1'/> A Review of Activity Indices and Efficacy End Points for Clinical Trials of Medical Therapy in Adults With Ulcerative Colitis显示文摘 | Geert D’Haens William J. Sandborn Brian G. Feagan Karel Geboes Stephen B. Hanauer E. Jan Irvine Marc Lémann Philippe Marteau Paul Rutgeerts Jurgen Sch?lmerich Lloyd R. Sutherland | 2007 | Gastroenterology2007，，2： | 2 |
| 9 | 生物学疗法在亚洲炎症性肠病患者中的应用前景显示文摘在不断揭秘炎症性肠病(IBD)发病机制的过程中,发现越来越多的具有治疗干预作用的靶点。目前一般认为溃疡性结肠炎(UC)与克罗恩病(CD)均是肠道对尚未明确的环境触发因素发生过度免疫反应所致。这一概念开启了发展针对肠道微观生物医学(the intestinal microbiome)进行干预治疗的设想。 | Hanauer SB 郑家驹(译) | 2008 | 中华消化杂志2008，28，12： | 2 |
| 10 | Randomised clinical trial: the safety and tolerability of T richuris suis ova in patients with Crohn’s disease显示文摘 | W. J. Sandborn D. E. Elliott J. Weinstock R. W. Summers A. Landry‐Wheeler N. Silver M. D. Harnett S. B. Hanauer | 2013 | Aliment Pharmacol Ther2013，，3： | 2 |
| 11 | Continuous Therapy With Certolizumab Pegol Maintains Remission of Patients With Crohn’s Disease for up to 18 Months显示文摘 | Gary R. Lichtenstein Ole ?. Thomsen Stefan Schreiber Ian C. Lawrance Stephen B. Hanauer Ralph Bloomfield William J. Sandborn | 2010 | Clinical Gastroenterology and Hepatology2010，，7： | 2 |
| 12 | Effects of Vedolizumab Induction Therapy for Patients With Crohn’s Disease in Whom Tumor Necrosis Factor Antagonist Treatment Had Failed显示文摘 | Bruce E. Sands Brian G. Feagan Paul Rutgeerts Jean-Frédéric Colombel William J. Sandborn Richmond Sy Geert D’Haens Shomron Ben-Horin Jing Xu Maria Rosario Irving Fox Asit Parikh Catherine Milch Stephen Hanauer | 2014 | Gastroenterology2014，，： | 2 |
| 13 | Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis显示文摘 | Sunanda Kane Dezheng Huo James Aikens Stephen Hanauer | 2003 | The American Journal of Medicine2003，，1： | 2 |
| 14 | <ce:link locator='fx1'/> A Review of Activity Indices and Efficacy End Points for Clinical Trials of Medical Therapy in Adults With Ulcerative Colitis显示文摘 | Geert D'Haens William J. Sandborn Brian G. Feagan Karel Geboes Stephen B. Hanauer E. Jan Irvine Marc Lémann Philippe Marteau Paul Rutgeerts Jurgen Sch?lmerich Lloyd R. Sutherland | 2007 | Gastroenterology2007，，2： | 2 |
| 15 | Intestinal epithelial vitamin D receptor signaling inhibits experimental colitis显示文摘 | Liu Weicheng Chen Yunzi Golan Maya Aharoni Annunziata Maria L Du Jie Dougherty Urszula Kong Juan Musch Mark Huang Yong Pekow Joel Zheng Changqing Bissonnette Marc Hanauer Stephen B Li Yan Chun | 2013 | Journal of Clinical Investigation2013，，9： | 2 |
| 16 | Medical therapy for ulcerative colitis显示文摘 | HANAUER B | 2004 | Gastroenterol2004，126，： | 1 |
| 17 | Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial显示文摘 | HANAUER SB FEAGAN BG LICHTENSTEIN GR | 2002 | Lancet2002，359，9317： | 1 |
| 18 | Oral Pentasa in the treatment of active Crohn's disease:A meta-analysis of double-blind,placebo-controlled trials显示文摘 | Hanauer SB Strmberg U | 2004 | Clin Gastroenterol Hepatol2004，2，5： | 1 |
| 19 | Review article:high-dose am inosalicylates to induce and maintain remissions in ulcerative colitis显示文摘 | Hanauer SB | 2006 | Aliment Pharmacol Ther2006，24，3： | 1 |
| 20 | Budesonide CIR capsules (once or twice daily divided-dose ) in active Crohn' s disease : a randomized placebo-controlled study in the United States 显示文摘 | Tremaine WJ Hanauer SB Katz S | 2002 | Am J Gastroenterol2002，97，7： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员